Featured Research

from universities, journals, and other organizations

Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests

Date:
May 29, 2000
Source:
Vanderbilt University Medical Center
Summary:
An enzyme implicated in colon cancer may also play a role in other cancers by promoting development of blood vessels to feed tumors, a Vanderbilt-Ingram Cancer Center scientist and his colleagues report.

NASHVILLE, Tenn. - An enzyme implicated in colon cancer may also play a role in other cancers by promoting development of blood vessels to feed tumors, a Vanderbilt-Ingram Cancer Center scientist and his colleagues report.

Related Articles


Writing in the June 1 issue of the Journal of Clinical Investigation, the researchers report that lung tumors in animal models grew at a slower pace when the gene for this enzyme (cyclooxygenase-2 or COX-2) was deliberately eliminated. In addition, tumor growth was significantly reduced by treatment with a drug to block COX-2 in animals that had the active COX-2 gene.

Upon closer examination, they found that, in the absence of COX-2, the tumors developed about 30 percent fewer blood vessels than those in the animals whose COX-2 gene was present and active. They also found that COX-2 levels were directly associated with levels of a growth factor that promotes the development of new blood vessels, a process called angiogenesis. In the cells missing the COX-2 gene, VEGF levels were substantially lower; with an active COX-2 gene, VEGF levels dropped after treatment with COX-2 inhibitors.

"It appears that the inhibition of tumor growth is due to lack of tumor-associated angiogenesis," said Raymond DuBois, MD, PhD, Mina Cobb Wallace Professor and Associate Director of Cancer Prevention at Vanderbilt-Ingram. "We are now examining exactly how that is controlled."

The link that is beginning to be established between COX-2 and angiogenesis - by these scientists and others - is important because it suggests selective COX-2 inhibitors might be useful as potential treatments for already established tumors.

Initially developed for arthritis, these drugs are similar to aspirin and non-steroidal anti-inflammatory drugs like ibuprofen. Aspirin and NSAIDs target both forms of the enzyme cyclooxygenase (1 and 2), both of which lead to the production of bio-active lipid hormones such as prostaglandins. Newer drugs, including the widely prescribed and marketed drug Celebrex, target only COX-2. This selectivity results in relief from pain and inflammation promoted by COX-2's prostaglandin products but leaves intact the stomach protection provided by COX-1's products.

Strong evidence over more than a decade has associated longterm use of aspirin and/or NSAIDs with a reduced risk for colon cancer. DuBois and his colleagues made the important link several years ago between elevated levels of COX-2 and the development of colon tumors. Now, DuBois is a national co-investigator in a multi-center study to test the ability of COX-2 inhibitors to prevent precancerous polyps in the colon.

In recent years, cancer researchers have turned to the field of angiogenesis as a hopeful avenue to fight cancer by more indirect means than traditional chemo- or radiation therapy. Tumors produce growth factors, such as VEGF, to recruit new blood vessels to bring the oxygen and nutrients the tumors need to grow. These vessels also provide a route for metastasis (spread of cancer cells to other parts of the body).

A number of drugs that interfere with that process are being studied in the laboratory setting as well as in patients. These drugs include an antibody that directly inhibits the action of VEGF. Scientists are also working to better understand angiogenesis in order to develop more effective means of cutting off tumor supply lines.

DuBois' colleagues in the research reported in JCI were Christopher Williams, also of the Vanderbilt-Ingram Cancer Center; Masahiko Tsujii of Osaka School of Medicine; and Jeff Reese and Sudhansu Dey of the University of Kansas Medical Center.

The work was supported by the T.J. Martell Foundation, which funds the Frances Williams Preston Laboratories at Vanderbilt-Ingram, an National Cancer Institute-designated cancer center.


Story Source:

The above story is based on materials provided by Vanderbilt University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Vanderbilt University Medical Center. "Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests." ScienceDaily. ScienceDaily, 29 May 2000. <www.sciencedaily.com/releases/2000/05/000526071547.htm>.
Vanderbilt University Medical Center. (2000, May 29). Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2000/05/000526071547.htm
Vanderbilt University Medical Center. "Asprin-Like Drugs May Be Useful For Cancer Treatment, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2000/05/000526071547.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins